GSKGlaxoSmithKlineRunning, no new patients
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
Neoplasms, Rectal
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 154 (final count)
- Started
- Apr 3, 2023
- Main results expected
- Nov 2, 2026
- Fully finished
- Oct 11, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR)
Measured over: 18 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05723562 · record last updated 2026-05-26 · checked 2026-11-09 15:42 UTC